Skip to main content

Dihydroergotamine News

Related terms: Dihydroergotamine Nasal

FDA Approves Brekiya (dihydroergotamine mesylate) Injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

BRIDGEWATER, N.J., May 15, 2025 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydr...

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

DURHAM, N.C., April 30, 2025 /PRNewswire/ – Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other...

FDA Approves Trudhesa (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine

SEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) – Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Migraine, Cluster Headaches, Headache

Dihydroergotamine patient information at Drugs.com